Clinically localised prostate cancer is microsatellite stable.

Clinically localised prostate cancer is microsatellite stable.

OBJECTIVES: To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables. MATERIALS AND METHODS: Two forms of MSI have been described...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Azzouzi, A, Catto, J, Rehman, I, Larre, S, Roupret, M, Feeley, K, Cussenot, O, Meuth, M, Hamdy, F
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	2007

Míreanna comhchosúla

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2003)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma.
de réir: Rouprêt, M, et al.
Foilsithe / Cruthaithe: (2005)

S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
de réir: Rouprêt, M, et al.
Foilsithe / Cruthaithe: (2008)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
de réir: Roupret, M, et al.
Foilsithe / Cruthaithe: (2008)

Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma.
de réir: Roupret, M, et al.
Foilsithe / Cruthaithe: (2004)

Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2003)

DNA promoter methylation in urothelial cancer: a feature of the invasive phenotype and a novel therapeutic target
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2006)

Compared performance of microsatellite and methylation urinalysis in predicting recurrence in transitional cell carcinoma and definition of a diagnostic panel of markers by bayesian network analysis
de réir: Roupret, M, et al.
Foilsithe / Cruthaithe: (2007)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2005)

Compared performance of microsatellite and methylation urinalysis in predicting recurrence in transitional cell carcinoma and definition of a diagnostic panel of markers by bayesian network analysis
de réir: Roupret, M, et al.
Foilsithe / Cruthaithe: (2007)

Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2004)

Molecular diagnosis of localized prostate cancer by quantitative methylation-specific PCR gene patterns in urine cells obtained by prostate massage
de réir: Roupret, M, et al.
Foilsithe / Cruthaithe: (2007)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
de réir: van Oers, J, et al.
Foilsithe / Cruthaithe: (2009)

Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
de réir: Rouprêt, M, et al.
Foilsithe / Cruthaithe: (2007)

A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
de réir: Rouprêt, M, et al.
Foilsithe / Cruthaithe: (2008)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
de réir: Evans, C, et al.
Foilsithe / Cruthaithe: (2009)

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas
de réir: Ahmad, M, et al.
Foilsithe / Cruthaithe: (2003)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2003)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
de réir: Lane, J, et al.
Foilsithe / Cruthaithe: (2009)

Tissue microarray immunohistochemistry and cluster analysis confirms the validity of candidate proteins in prostate cancer identified by proteomic analysis of urine
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
de réir: Hamdy, F, et al.
Foilsithe / Cruthaithe: (2006)

Behavior of urothelial carcinoma with respect to anatomical location.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2007)

Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
de réir: Lane, J, et al.
Foilsithe / Cruthaithe: (2004)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
de réir: Cross, S, et al.
Foilsithe / Cruthaithe: (2005)

Three dimensional ultrasound and prostate cancer.
de réir: Mehta, S, et al.
Foilsithe / Cruthaithe: (2004)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
de réir: Yates, DR, et al.
Foilsithe / Cruthaithe: (2005)

The use of proteomics in urological research
de réir: Rehman, I, et al.
Foilsithe / Cruthaithe: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
de réir: Yates, DR, et al.
Foilsithe / Cruthaithe: (2006)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
de réir: Lane, J, et al.
Foilsithe / Cruthaithe: (2007)

Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens.
de réir: Cussenot, O, et al.
Foilsithe / Cruthaithe: (2007)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
de réir: Catto, J, et al.
Foilsithe / Cruthaithe: (2011)

Gli1 appears to be constitutively expressed in the lumenal epithelial cells of the prostate but not in the basal cell layer or the mesenchyme
de réir: Spencer, A, et al.
Foilsithe / Cruthaithe: (2004)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
de réir: Dhawan, D, et al.
Foilsithe / Cruthaithe: (2006)

Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers
de réir: Baqir Hasan Jafry, et al.
Foilsithe / Cruthaithe: (2024-06-01)